Patent application number | Description | Published |
20090030020 | 7H-Pyrido[3,4-D]Pyrimidin-8-Ones, Their Manufacture and Use as Protein Kinase Inhibitors - Objects of the present invention are the compounds of formula I | 01-29-2009 |
20090162359 | BIVALENT, BISPECIFIC ANTIBODIES - The present invention relates to novel domain exchanged, bivalent, bispecific antibodies, their manufacture and use. | 06-25-2009 |
20090162360 | BIVALENT, BISPECIFIC ANTIBODIES - The present invention relates to novel domain exchanged, bivalent, bispecific antibodies, their manufacture and use. | 06-25-2009 |
20090175851 | BIVALENT, BISPECIFIC ANTIBODIES - The present invention relates to novel domain exchanged, bivalent, bispecific antibodies, their manufacture and use. | 07-09-2009 |
20090232811 | BIVALENT, BISPECIFIC ANTIBODIES - The present invention relates to novel domain exchanged, bivalent, bispecific antibodies, their manufacture and use. | 09-17-2009 |
20090247518 | 6-(2-ALKYL-PHENYL)-PYRIDO[2,3-D]PYRIMIDINES USEFUL AS PROTEIN KINASE INHIBITORS - Objects of the present invention are the compounds of formula I | 10-01-2009 |
20090318428 | HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS - Objects of the present invention are the compounds of formula I | 12-24-2009 |
20100041684 | PYRIMIDYL DERIVATIVES AS PROTEIN KINASE INHIBITORS - Objects of the present invention are the compounds of formula (I), their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, medicaments containing them and their manufacture, as well as the use of the above compounds in the control or prevention of illnesses such as cancer. | 02-18-2010 |
20100081796 | BISPECIFIC ANTI-EGFR/ANTI-IGF-1R ANTIBODIES - The present invention relates to bispecific antibodies against EGFR and against IGF-1R, methods for their production, pharmaceutical compositions containing said antibodies, and methods of treatment using the antibodies. | 04-01-2010 |
20100111967 | BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES - The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 05-06-2010 |
20100254988 | Bispecific Anti ErbB2 / Anti cMet Antibodies - The present invention relates to bispecific antibodies against human ErbB-2 and against human c-Met, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof. | 10-07-2010 |
20100254989 | Bispecific Anti ErbB1 / Anti c Met Antibodies - The present invention relates to bispecific antibodies against human ErbB-1 and against human c-Met, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof. | 10-07-2010 |
20100316645 | Bispecific Antigen Binding Proteins - The present invention relates to bispecific antigen binding proteins, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 12-16-2010 |
20100322934 | Bispecific, Tetravalent Antigen Binding Proteins - The present invention relates to bispecific, tetravalent antigen binding proteins, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 12-23-2010 |
20100322935 | Tri- or Tetraspecific Antibodies - The present invention relates to tri- or tetraspecific antibodies, their manufacture and use. | 12-23-2010 |
20110236388 | BISPECIFIC, BIVALENT ANTI-VEGF/ANTI-ANG-2 ANTIBODIES - The present invention relates to bispecific, bivalent antibodies against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 09-29-2011 |
20120149879 | BISPECIFIC ANTI-EGFR/ANTI-IGF-1R ANTIBODIES - The present invention relates to bispecific antibodies against EGFR and against IGF-1R, methods for their production, pharmaceutical compositions containing said antibodies, and methods of treatment using the antibodies. | 06-14-2012 |
20120164726 | BIVALENT, BISPECIFIC ANTIBODIES - The present invention relates to a host cell for use in the expression of a novel domain exchanged, bivalent, bispecific antibody. | 06-28-2012 |
20120225071 | BIVALENT, BISPECIFIC ANTIBODIES - The present invention relates to nucleic acids which encode the heavy chains and light chains of a novel domain exchanged, bivalent, bispecific antibody, and vectors comprising the same. | 09-06-2012 |
20120237506 | Antigen Binding Proteins - The present invention relates to antigen binding proteins comprising two Fc parts, methods for their production, pharmaceutical compositions containing said antigen binding proteins, and uses thereof. | 09-20-2012 |
20120237507 | Monovalent Antigen Binding Proteins - The present invention relates to monovalent antigen binding proteins with a CH1-CL domain exchange, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 09-20-2012 |
20120321627 | BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES - The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 12-20-2012 |
20130058937 | Bispecific antigen binding molecules - The present invention generally relates to novel bispecific antigen binding molecules. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease. | 03-07-2013 |
20130060011 | FC-FREE ANTIBODIES COMPRISING TWO FAB FRAGMENTS AND METHODS OF USE - The present invention relates to bispecific antibodies comprising at least two fab fragments, wherein the first Fab fragment comprises at least one antigen binding site specific for a first antigen; and the second Fab fragment comprises at least one antigen binding site specific for a second antigen, wherein either the variable regions or the constant regions of the second Fab heavy and light chain are exchanged; and wherein the bispecific antibody is devoid of a Fc domain; methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 03-07-2013 |
20130156772 | Bispecific Anti ErbB1 / Anti cMet Antibodies - The present invention relates to bispecific antibodies against human ErbB-1 and against human c-Met, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof. | 06-20-2013 |
20130273054 | Bispecific Anti ErbB2/Anti cMet Antibodies - The present invention relates to bispecific antibodies against human ErbB-2 and against human C-met, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof. | 10-17-2013 |
20130344094 | POLYPEPTIDE-POLYNUCLEOTIDE-COMPLEX AND ITS USE IN TARGETED EFFECTOR MOIETY DELIVERY - Herein is reported a polypeptide-polynucleotide-complex as therapeutic agent and its use as tool for the targeted delivery of an effector moiety. The polynucleotide part of the complex is essentially resistant to proteolytic and enzymatic degradation in vivo. Additionally the polypeptide part specifically binds to a compound or structure such as a tissue or organ, a process or a disease. Thus, one aspect as reported herein is a polypeptide-polynucleotide-complex comprising a) a polypeptide specifically binding to a target and conjugated to a first member of a binding pair, b) a polynucleotide linker conjugated at its first terminus to the second member of the binding pair, and c) an effector moiety conjugated to a polynucleotide that is complementary to at least a part of the polynucleotide linker. | 12-26-2013 |
20140120613 | BIVALENT, BISPECIFIC ANTIBODIES - The present invention relates to a host cell for use in the expression of a novel domain exchanged, bivalent, bispecific antibody. | 05-01-2014 |
20150030598 | TRI- OR TETRASPECIFIC ANTIBODIES - The present invention relates to tri- or tetraspecific antibodies, their manufacture and use. | 01-29-2015 |
20150044214 | BISPECIFIC, TETRAVALENT ANTIGEN BINDING PROTEINS - The present invention relates to bispecific, tetravalent antigen binding proteins, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 02-12-2015 |